Rechercher des projets européens

5 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 
"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Voir le projet

 8

 TERMINÉ 
In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerg ...
Voir le projet

 12

 TERMINÉ 
Histopathology has traditionally been a low-throughput, labour-intensive technique. Conventional manual annotation of tissue slides requires a pathologist to examine the tissue and cellular components to grade the level of disease progression. However, digital pathology and automated digital image analysis solutions can provide a more rapid solution. In recent years, there has been a rapid uptake ...
Voir le projet

 6

 TERMINÉ 

Apoptosis Modelling for Treatment Decisions in Colorectal Cancer (APO-DECIDE)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2014,

"With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, personalised cancer treatment is at the door step of clinical practise. This progress in drug development contrasts strikingly with current clinical practice, where decision making depends largely on clinical factors such as tumour staging and age of patient, with t ...
Voir le projet

 7

 TERMINÉ 
Inhibition of angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a well established therapeutic strategy against cancer. Inhibitors of angiogenesis have been developed to block tumour growth and metastasis, and a number of these inhibitors are now clinically approved. However, contrary to initial expectations, angiogenesis inhibitors can cause a range of toxicities ...
Voir le projet

 11